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ABSTRACT
We provide direct evidence that overexpression of p53 is not sufficient
for robust p53-dependent activation of the endogenous gadd45 gene. When
p53 was induced in TR9-7 cells in the absence of DNA damage, waf1/p21
and mdm2 mRNA levels were increased, but a change in gadd45 mRNA
was barely detectable. Activation of the gadd45 gene was observed when
camptothecin was added to cells containing p53 in the absence of a further
increase in the p53 level. Phosphorylation of p53 at serine 15 and acety-
lation at lysine 382 were detected after drug treatment. It has been
suggested that p53 posttranslational modification is critical during acti-
vation. However, inhibition of these modifications by wortmannin was not
sufficient to block the transactivation of gadd45. Interestingly, after camp-
tothecin treatment, increased DNase I sensitivity was detected at the
gadd45 promoter, suggesting that an undetermined DNA damage signal is
involved in inducing chromatin remodeling at the gadd45 promoter while
cooperating with p53 to activate gadd45 transcription.
INTRODUCTION
The p53 tumor suppressor is a nuclear protein that responds to
DNA damage to preserve genomic integrity. Upon DNA damage, p53
is stabilized and posttranslationally modified (1). p53 is a transcription
factor that can activate transcription of many target genes in the
absence of DNA damage. Three p53 target genes that have been well
described include waf1/p21, gadd45, and mdm2. waf1/p21 is an
inhibitor of cyclin-dependent kinases. It inhibits the phosphorylation
of Rb and blocks cell cycle progression from G1 to S phase (2).
gadd45 (growth arrest and DNA damage 45) was first identified as a
gene that was rapidly induced after IR
3 of lymphoblasts and fibro-
blasts (3, 4). The gadd45 protein can interact directly with the essen-
tial replication factor proliferating cell nuclear antigen, may block
DNA replication, and may coordinately enhance nucleotide excision
repair of damaged DNA (5). An auto-regulatory feedback loop is
formed between p53 and mdm2, whereby Mdm2 protein keeps p53
under negative control (6–9). The protein products of the p53 target
genes have an intriguingly diverse number of functions. Does p53 turn
on all its target genes at the same time? Do posttranslational modifi-
cations play a role in controlling the regulation of different targets?
These are questions that are being addressed by a number of labora-
tories working in the p53 field. Recent evidence suggests that p53
target genes can be differentially regulated. The topoisomerase poison
etoposide has been shown to inhibit mdm2 synthesis while increasing
waf1/p21 and gadd45 gene expression (10).
Two model systems have been used to study transcriptional regu-
lation by p53: (a) one is the stabilization of p53 through DNA
damage; and (b) the other is the overexpression of p53 by either
inducible promoters or temperature-sensitive alleles. Increased p53
levels are found in both systems, but DNA damage also triggers
posttranslational modifications of p53. DNA damage has also been
shown to trigger p53-mediated transcription of the gadd45 gene, but
it has not been determined whether this is the result of an increase in
the p53 level or a change in the p53 posttranslational modification. In
the p53 inducible cell line TR9-7, the removal of tetracycline causes
an increase in p53 that elicits the transactivation of the p21 gene. This
evokes both a G1-S and a G2-M cell cycle arrest (11). Because high
levels of p53 in this cell line are able to rapidly transactivate
waf1/p21, it has been assumed that p53 would also rapidly activate
other p53 inducible genes, including gadd45. It is known that DNA
damage activates signal transduction pathways that, in turn, activate
p53 by posttranslational modification (12). However, waf1/p21 can be
activated in the absence of these signals. Members of the PI3k-related
kinase superfamily can phosphorylate p53 at serine 15 and serine 37
(12). In vitro studies have demonstrated that ATM phosphorylates p53
at a single residue, serine 15. They also suggest a direct role for ATM
and related kinases in the DNA damage-induced phosphorylation of
serine 15 (13–15). Therefore, it was important for a study to be done
that would examine the activation of p53 target genes by constant p53
levels in both the presence and absence of DNA damage to determine
whether combinatorial signal transduction pathways could modify the
regulation of any p53 target genes. Such a study is presented here and
shows that differences in the ability of p53 to activate gadd45 in the
presence or absence of DNA damage were not dependent on a change
in the nuclear protein level of the tetracycline-regulated overexpressed
wt p53. gadd45 mRNA was only significantly accumulated when the
cell line containing wt p53 was treated with CPT. Phosphorylation of
p53 at serine 15 and acetylation at lysine 382 were detected after CPT
treatment, but inhibition of phosphorylation at serine 15 and acetyla-
tion at lysine 382 were not sufficient to block the transactivation of the
gadd45 gene. These data suggest that after DNA damage, a signal
triggered functional p53 to rapidly activate the gadd45 gene for
increased transcription, but this signal did not require the phosphory-
lation-acetylation cascade previously thought to be critical.
MATERIALS AND METHODS
Cell Lines. The MDAH041 cell line is a human fibroblast cell line lacking
functional p53 protein due to a frameshift mutation of one p53 allele at codon
184 and loss of the normal p53 allele (11). The TR9-7 cell line is an isogenic
cell line derived from MDAH041 that contains tetracycline-regulated wt p53
(both were generously provided by Munna Agarwal, The Cleveland Clinic
Foundation, Cleveland) (11). The 184A1 cell line is an immortalized human
mammary epithelial cell line that contains wt p53 (16). This cell line was
obtained from American Type Culture Collection.
DNase I Treatment of Nuclei. 184A1 cells were grown on 150-mm plates
at 37°C in a 1:1 mixture of Ham’s F-12 medium and DMEM containing 0.1
mg/ml cholera enterotoxin, 10 mg/ml insulin, 0.5 mg/ml hydrocortisol, 20
ng/ml epidermal growth factor, and 5% horse serum. TR9-7 cells were grown
on 150-mm plates at 37°C in DMEM containing 10% fetal bovine serum and
2 mg/ml tetracycline until 70% confluence. Subconfluent plates were grown
either in media containing tetracycline (control) for 24 h, withdrawal of
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1711tetracycline (2Tet) for 24 h, or after 24 h withdrawal of tetracycline with
overlapping 0.1 mM CPT treatment for the last4h( 2Tet & CPT). The isolated
nuclei were treated with increasing amounts of DNase I (Worthington; 2932
units/mg) for 10 min at 37°C as described previously (17).
DNA and RNA Analysis. DNase I-treated genomic DNA (20 mg) was
digested with XbaI to completion. The digested DNA was electrophoresed on
a 0.8% agarose gel and transferred to nylon membrane. The blots were
hybridized with a XbaI-MscI gadd45 probe (see Fig. 6). Cytoplasmic RNA was
isolated from MDAH041 and TR9-7 cells according to Maniatis as described
previously (17). Polyadenylated RNA was prepared using mini-oligo dT spin
columns. Either 1.5 mg of polyadenylated RNA or 25 mg of cytoplasmic RNA
from each sample were electrophoresed on a 1% formaldehyde-agarose gel and
transferred onto nylon membrane. The blot was hybridized with full-length
cDNA probes for human gadd45, mdm2, and waf1/p21. The GAPDH probe
was obtained as a 1.25-kb cDNA PstI fragment (18). All probes were labeled
with
32P by random prime labeling.
Real-Time PCR with Molecular Beacon. For RT of each sample, 5 mgo f
cytoplasmic RNA were incubated at 65°C for 10 min with 250 mmol of
oligo(dT)15 primer (Boehringer Mannheim) in a total volume of 10 ml. After
cooling on ice, 10 mlo fR Tm i x[ 2 3 AMV, 15 units of AMV reverse
transcriptase (Amersham), 2.5 mM deoxynucleotide triphosphate, and 20 units
of RNase inhibitor RNasin (Promega)] were added. Samples were incubated
f o r1ha t37°C. The reaction was stopped by heating at 94°C for 2 min.
Samples were stored at 280°C.
For PCR with molecular beacons, PCR primer pairs were designed to anneal
to their target at the same temperature (55°C) and to amplify DNA fragments
of approximately 100 bp. Molecular beacons were designed with a DNA
folding program
4 to have a hairpin stem that dissociates at a temperature 10°C
higher than the detection temperature. The molecular beacons were synthe-
sized as described previously (19).
Two ml of RT products were used in the PCR reaction carried out under the
following conditions: 13 TaqMan buffer (Perkin-Elmer), 2.5 mM MgCl2, 250
mM deoxynucleotide triphosphate, 15 pmol of each primer, 2.5 units of Am-
pliTaq Gold polymerase (Perkin-Elmer), and 125 ng of the appropriate mo-
lecular beacon. Forty cycles of amplification (94°C denaturation for 30 s, 55°C
annealing for 1 min, and 72°C elongation for 30 s) were carried out in sealed
tubes in an Applied Biosystems 7700 Prism spectrofluorometric thermal cycler
(Perkin-Elmer). Fluorescence was measured during the annealing step and
plotted automatically for each sample.
The primer pairs used for PCR reaction were synthesized by Operon and
were as follows: (a) gadd45, 59-CCATGCAGGAAGGAAAACTATG-39 (for-
ward primer) and 59-CCCAAACTATGGCTGCACACT-39 (antisense primer);
and (b) GAPDH, 59-AGAGCACAAGAGGAAGAGAGAGACC-39 (forward
primer) and 59-AACTGTGAGGAGGGGAGATTCAG-39 (antisense primer).
The sequences of the molecular beacons were as follows: (a) gadd45,
59-CGCTGCAGAATGGTTGAGTTACATTAAAATAAACCGCAGCG-39;
and (b) GAPDH, 59-GGACGCGGTGGGGGACTGAGTGTGGCGTCC-39.
Preparation of Nuclear Protein Extracts. Nuclear lysates were prepared
as described previously (17). To prevent rapid deacetylation, trichostatin A, an
inhibitor of histone deacetylases, was added in the nuclear extraction buffer at
a final concentration of 5 mM (20). Wortmannin is a fungal metabolite that has
been shown to act as a selective inhibitor of PI3k family members (21). TR9-7
cells were incubated in 5 mM wortmannin for 4 h before cells were lysed.
Western Blot Analysis. Nuclear lysates were prepared from cells main-
tained as described above. Samples were electrophoresed on a 10% SDS-
PAGE and electrotransferred to nitrocellulose membrane. The blots were
probed with specific antibodies as described and visualized by incubation with
either goat antimouse or goat antirabbit secondary antibody followed by ECL
solutions. The p53-specific anti-phosphoserine-15 antibody and anti-acetylated
lysine 382 antibody were produced as described previously (22).
Ligation-mediated PCR for in Vivo Footprinting. The ligation-mediated
PCR in vivo footprinting was carried out as described previously (17). The
following primers were used: (a) oligonucleotide 1, 59-CCCTGAAAACATA-
ACTTCCC-39;( b) oligonucleotide 2, 59-GAAGCTGACTCCTTAATGAG-
GG-39; and (c) oligonucleotide 3, 59-TGACTCCTTAATGAGGGGTGAGC-
CAG-39.
EMSA. The SCS synthetic oligonucleotide used in this study contained
consensus p53 binding sites. The sequence of this oligonucleotide was
59-TCGAGCCGGGCATGTCCGGGCATGTCCGGGCATGTC- 39.
Labeling of the oligonucleotides was performed with the large fragment of
DNA polymerase and [
32P]dCTP. Reaction mixtures for EMSA experiments
4 http:www.ibc.wustl.edu/;zuker/dna/form1.cgi.
Fig. 1. Differential activation of wt p53 target genes occurs after CPT-induced DNA
damage. The RNA extraction was made from cells grown in media containing tetracycline
(Control), after a 24-h withdrawal of tetracycline (2Tet), or after a 24-h withdrawal of
tetracycline with overlapping 0.1 mM CPT treatment for the last4h( 2Tet & CPT).
Northern blot analysis of the wt p53-responsive genes was carried out by separating 25 mg
of cytoplasmic RNA in a 1% formaldehyde-agarose gel and transferring the RNA to a
nylon membrane. The blot was hybridized with full-length cDNA probes for waf1,
gadd45, mdm2, and GAPDH as indicated. The results were reproducibly obtained in
multiple blots using both mRNA and total cytoplasmic RNA. The signals were analyzed
using a Molecular Dynamics PhosphorImager with Image Quant software.
Fig. 2. p53 protein levels in MDAH041 and TR9-7 nuclear extract. A, 100 mgo f
nuclear protein were resolved by electrophoresis on a 10% SDS-PAGE. The p53 in
samples was visualized by Western blotting with the p53-specific monoclonal antibody
PAb240 and detected with ECL reagent. B, the blot was reprobed with anti-actin antibody
as a control of loading.
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7.8), 100 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mg of sonicated salmon sperm
DNA, and 10% glycerol. In addition to 2 mg of MDAH041 or TR9-7 nuclear
protein extract, 0.5 mg of PAb1801 was added to each reaction. All samples
were incubated at room temperature for 20 min. The protein-DNA complexes
were resolved on a 4% acrylamide gel.
RESULTS
Differential Activation of p53-responsive Genes waf1, mdm2,
and gadd45. The tetracycline-regulated wt p53-expressing cell line
TR9-7 and its isogenic p53-negative partner MDAH041 (11) were
used to analyze p53-mediated transactivation of waf/p21, mdm2, and
gadd45 in the presence and absence of DNA damage (Fig. 1). It has
been shown that increased p53 DNA binding activity was detected
when fibroblasts were treated with 100 mM C P Tf o r4hb yatime
course assay (23). Barely detectable expression of the p53 target genes
was observed in RNA samples derived from MDAH041 cells before
drug treatment (Fig. 1, Lane 1). No change was observed for waf1/p21
after CPT treatment in the absence of p53, whereas a slight increase
was observed for both mdm2 and gadd45 (Fig. 1, Lane 2). The
activation resulting from the induced p53 or the induced p53 in the
presence of CPT was examined using the inducible cell line TR9-7.
Induction of p53 by the withdrawal of tetracycline caused a 5-fold
increase for both waf1/p21 and mdm2 RNAs above those seen in the
controls (Fig. 1, A and C, compare Lanes 3 and 4). The waf1/p21 gene
was activated to the same extent with or without the addition of CPT
(Fig. 1A, Lanes 4 and 5). Interestingly, in the TR9-7 cells, although no
activation of gadd45 RNA was detected after tetracycline withdrawal,
an 8.8-fold activation was observed when the induced cells were
incubated with CPT (Fig. 1B, compare Lanes 3–5). In addition, the
mdm2 gene was activated in a p53-dependent manner when tetracy-
cline was removed (Fig. 1C, Lane 4), but the mdm2 RNA level
decreased when the cells were treated with CPT (Fig. 1D, Lane 5). A
similar result showing inhibition of mdm2 in the presence of etoposide
was recently reported (10).
p53 Nuclear Protein Level Does Not Correlate with Transcrip-
tion Activity. Increased levels of nuclear p53 protein often result
from treating cells with DNA-damaging agents (1). We examined the
p53 protein level in the presence and absence of drug to see whether
the differential activation of the p53-responsive gene gadd45 corre-
sponded to an increase in nuclear p53 (Fig. 2). The protein level was
detected by Western blotting with the p53-specific monoclonal anti-
body PAb240. Nuclear p53 protein was induced after the withdrawal
of tetracycline for 24 h, and the protein level did not change after CPT
treatment (Fig. 2A, Lanes 4 and 5). Therefore, it appeared that an
increased level of p53 protein in the nucleus was not required for the
p53-dependent CPT-mediated induction of gadd45.
p53 Is Phosphorylated at Serine 15 and Acetylated at Lysine
382 in Response to CPT Treatment, and These Modifications Can
Be Inhibited by Wortmannin in Vivo. Posttranslational modifica-
tion of p53 has been suggested as one mechanism that regulates p53
activity. gadd45 can be activated by an ATM and p53-dependent
mechanism mediated by the p53-RE in intron 3 (4). In vitro studies
have demonstrated that ATM phosphorylates p53 at a single residue,
serine 15 (13, 14). We analyzed the DNA damage-induced phospho-
rylation status of p53 using the p53 specific anti-phosphoserine-15
antibody. Similarly, we analyzed the DNA damage-induced acetyla-
tion of p53 using a p53-specific anti-acetylated lysine 382 antibody.
Western blot results demonstrated that p53 was phosphorylated at
serine 15 only when CPT was added (Fig. 3A, Lane 3). Likewise,
acetylation at lysine 382 was induced after treatment with CPT (Fig.
3B). These results correlate differential posttranslational modification
Fig. 3. Wortmannin inhibits CPT-activated phosphorylation of p53 at serine 15 and
acetylation at lysine 382 in vivo. A, 100 mg of nuclear protein (same samples as Fig. 2)
were resolved by electrophoresis on a 10% SDS-PAGE. The phosphorylated serine 15 in
samples was visualized by Western blotting with a specific antibody (anti-phosphorylated-
serine 15) and detected with ECL reagent. B, the acetylated lysine 382 in samples was
detected by Western blotting with a specific antibody (anti-acetylated lysine 382). The
nuclear protein extraction buffer contained 5 mM trichostatin A. The blot was also probed
with PAb240 to detect total p53. C, nuclear extract was made from the TR9-7 cells grown
in media containing 5 mM wortmannin for the last 4 h. Nuclear extract (100 mg) was
resolved by electrophoresis on a 10% SDS-PAGE and transferred to nitrocellous paper.
The blot was probed with anti-phosphorylated serine15, anti-acetylated lysine 382, and
PAb240 as indicated.
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gadd45 gene.
An inhibitor that could block phosphorylation of p53 was added to
examine whether phosphorylation of p53 at serine 15 was required for
activation of gadd45. In vitro studies have shown previously that
wortmannin can inhibit phosphorylation of p53 at serine 15 by block-
ing both DNA-PK and ATM kinase activity (22, 13). Additionally, it
was reported that wortmannin inhibits actinomycin D-induced activa-
tion of a p53 chloramphenicol acetyltransferase reporter construct
(24). Wortmannin is a specific inhibitor of PI3k but does not affect
protein kinase C, cAMP- or cGMP-dependent kinase, c-src, phospho-
lipase C, or calmodulin-dependent protein kinase (25). The posttrans-
lational modification of p53 derived from cells grown in media
containing wortmannin for the last4ho fgrowth before protein
extraction was analyzed (Fig. 3C, Lanes 1–3). Wortmannin reduced
both in vivo phosphorylation of serine 15 and acetylation of lysine 382
(Fig. 3C, compare Lane 3 with Lane 4). Wortmannin did not alter the
induction or level of p53 in the TR9-7 cells (Fig. 3C, with antibody
PAb240). It has been shown in vitro that acetylation of p53 at lysine
382 is dependent on NH2-terminal phosphorylation (20). Our results
Fig. 4. Wortmannin does not block DNA damage induction of the gadd45 gene. Analysis of gadd45 mRNA expression was analyzed by real-time RT-PCR using specific sequence
molecular beacons. A, molecular beacons are hairpin-shaped oligonucleotide probes that consist of a central part complementary to the target mRNA, flanked by two 6-bp inverted
repeats that can form a stable stem. The 59-end of the beacon is coupled to a fluorophore, whereas the 39-end is coupled to a quencher. In the absence of the target, the stem is closed,
and the fluorophore is quenched, whereas in the presence of the target, an opened conformation allows the fluorophore to fluoresce. B, the PCR was carried out in a spectrofluorometric
thermal cycler that monitored the fluorescence in each reaction tube at the annealing stage of each thermal cycle. The four reactions shown in the left panel correspond to PCR done
with increasing amounts of GAPDH-plasmid DNA (10
3-10
6 copies). The cycle at which the fluorescence signal becomes detectable above the background gives the threshold cycle.
An inverse relationship between the threshold cycle and the logarithm of the initial number of template was observed (right panel). C, The RT reactions were carried out with 5 mg
of cytoplasmic RNA, and 1 of 10 of the RT products was used in the PCR reactions specific for Gadd45 and GAPDH. The initial number of targets in each sample was calculated
according to the threshold cycle. The results were normalized using the control samples and the GAPDH values to give relative units of mRNA induction.
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cascade.
Phosphorylation at Serine 15 and Acetylation at Lysine 382 Are
Not Necessary to Control p53-mediated Activation of gadd45
Expression. It has recently become clear that real-time RT-PCR
analysis with novel fluorescent molecular beacon probes is a more
rapid method for quantitative analysis of mRNA accumulation (19,
26). Therefore, a molecular beacon designed for the gadd45 gene was
used to investigate the levels of gadd45 mRNAs in the presence or
absence of wortmannin (Fig. 4). We investigated whether there was
any reduction in p53-mediated gadd45 gene expression when wort-
mannin was present because wortmannin reduced CPT-induced phos-
phorylation of p53 at serine 15 and acetylation at lysine 382 (Fig. 3).
Cytoplasmic RNA was extracted from TR9-7 cells incubated with or
without wortmannin for the last 4 h of growth. The mRNA level of
gadd45 in the TR9-7 cells was observed not to increase when p53 was
induced by the removal of tetracycline (Fig. 4C). However, a 7-fold
increase was detected when cells with induced p53 were treated with
CPT (Fig. 4C). The addition of wortmannin did not inhibit the
p53-mediated transcriptional activation of gadd45 (Fig. 4C). This
result suggests that CPT-induced DNA damage does not require the
phosphorylation of p53 at serine 15 to effect the activation of gadd45.
CPT-induced damage activates a yet to be determined component of
the p53-dependent signal transduction cascade that does not appear to
be a PI3k family member. In fact, the addition of wortmanin facili-
tated the ability of p53 to activate gadd45 in the absence of DNA
damage, suggesting that a PI3k member can act to inhibit gadd45
activation. Only a slight increase in gadd45 accumulation was de-
tected in the MDAH041 cell line without p53 in the presence of either
CPT or wortmannin (Fig. 4C).
DNA Binding by p53 Was Not Stimulated by CPT Treatment.
It is believed that p53 activates its target genes in part by the inter-
action of p53 with its recognition sequences. In fact, in vitro studies
have demonstrated that the acetylation of p53 at its COOH terminus
can stimulate the sequence-specific DNA binding activity of p53 (27).
To see whether activation of p53 DNA binding resulted after CPT
induced DNA damage, EMSAs were carried out with an oligonucleo-
tide containing the p53 SCS (28). The same p53-dependent gel shift
species was observed in both the 2Tet and 2Tet 1 CPT samples
(Fig. 5A, p53 arrow). In addition the p53-specific antibody PAb1801
was able to supershift this protein-DNA complex, further indicating
that this complex was p53 dependent (Fig. 5A, SP arrow). The EMSA
results also showed that p53, similar to the SCS oligonucleotide,
bound in both the presence and absence of CPT (Fig. 5A, Lanes 7–10).
Interestingly, the p53-specific antibody PAb421 could not supershift
the p53-DNA complex. This result suggests that there was another
modification at the COOH terminus, such as phosphorylation by
protein kinase C (29). We also observed the loss of PAb421 reactivity
by Western blot analysis. Because this loss of PAb421 reactivity was
detected using denatured and immobilized p53, it can be attributed to
the direct steric effect of an added phosphate (30). Similarly, we did
not observe increased p53 DNA binding activity to the gadd45 oli-
gonucleotide after drug treatment. Although the p53 gel shift results
were identical with both the SCS and gadd45 oligonucleotides, the
level of background obtained when the gadd45 oligonucleotide was
used was high; therefore, the SCS results are presented as the repre-
sentative sample.
Ligation-mediated PCR genomic footprinting was performed to
determine whether p53 bound to the gadd45 p53-RE in vivo and
whether binding changed on CPT treatment. We have previously
detected protection of the mdm2 p53-RE using this technique (17).
The putative p53-RE was identified by sequencing genomic gadd45
(Fig. 5B, Lanes A, T, G, and C). There was no DNase I protection of
Fig. 5. p53 DNA binding activity was not enhanced after DNA damage. A, the
electrophoretic mobility shift assay was carried out in the absence (Lanes 1, 3, 5,7, and 9)
or presence of p53 antibody PAb1801 (Lanes 2, 4, 6, 8, and 10). B, Genomic DNase I
footprinting was carried out on TR9-7 cells treated with 0.1 mg of DNase I. The published
putative p53-RE was identified by sequencing genomic gadd45 in a plasmid clone (Lanes
A, T, G, and C). Ligation-mediated PCR was performed, followed by primer extension
with
32P-labeled oligonucleotide 3, which hybridized approximately 150 bp downstream
from the gadd45 putative p53 binding site. Purified DNA digested with DraIII from
DNase I-untreated nuclei of TR9-7 (2Tet & CPT) cells was shown in Lane 6. Samples
were electrophoresed on a 6% urea sequencing gel.
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duced and activated by CPT (Fig. 5B, compare Lanes 2 and 3 with
Lane 1). Several DNase I hypercutting sites did emerge in a p53-
dependent manner (Fig. 5B, Lanes 2 and 3, arrow), which suggests
that p53 might bind transiently to the site and might be involved in a
modification of the nucleosomal structure in this area. Interestingly,
no change in the hypercutting sites was observed when CPT was
added. CPT forms a ternary complex with topoisomerase I and the
DNA, covalently trapping the topoisomerase I on the DNA (31).
gadd45 appears to facilitate topoisomerase activity in vivo (32).
Therefore, technically, we cannot rule out the possibility that there
might have been CPT-mediated DNA cleavage interfering with our
DNase I footprints when CPT was present. Clearly no increased
protection of the putative p53-RE in the gadd45 gene was detected on
activation of gadd45 transcription, although protection of the mdm2
p53-RE was detected under these conditions.
Increased DNase I Sensitivity Was Detected at the gadd45
Promoter Region when CPT Was Present. To determine whether
remodeling of the gadd45 gene chromatin was associated with gene
activation, Southern blot analysis using a probe to the far end of the
expected fragment was carried out under various conditions (Fig. 6C).
Selective, gene-specific changes in chromatin structure have emerged
from DNase I mapping studies that focused on the arrangement of
nucleosomes around specific genes as a function of their state of
transcriptional activity (33). We have previously shown that the
p53-RE of the mdm2 gene is constitutively DNase I sensitive (17). We
screened for the appearance of DNase I-hypersensitive sites at the
promoter and the putative p53-RE of the gadd45 gene. The DNase
I-treated genomes isolated from the nuclei of TR9-7 cells grown with
or without CPT treatment were analyzed (Fig. 6A). Two constitutive
DNase I-hypersensitive sites were observed in the gadd45 gene. One
hypersensitive site was observed 3 kb from the XbaI cutting site and
corresponded to the location of the putative p53-RE (Fig. 6). The
other hypersensitive site was observed 1.3 kb from the XbaI cutting
site and corresponded to the gadd45 promoter region (Fig. 6). The
overall DNase I sensitivity at the putative p53 binding sites did not
change in the presence of CPT. However, DNase I sensitivity at the
gadd45 promoter region was increased when CPT was added to the
TR9-7 cells (Fig. 6A). The 184A1 cell line is an immortalized human
mammary epithelial cell line that contains wt p53 (16). The 184A1
cell line was used to rule out the possibility that the increased DNase
I sensitivity that resulted in the TR9-7 cells was not due to the
artificial nature of the overexpressed p53. In the 184A1 cell line, the
p53 was only activated by the DNA damage induced by CPT, and
once again the same two constitutive DNase I-hypersensitive sites
were observed in the gadd45 gene, with increased sensitivity at the
gadd45 promoter resulting on CPT treatment (Fig. 6B). It has been
suggested that increased DNase I sensitivity can result as a conse-
quence of the absence of a canonical nucleosome or, alternatively, it
can result from binding of transcription factors that locally distort the
DNA within or adjacent to a site (34). Several transcription factors
have been found that are involved in the regulation of gadd45 gene
expression. Sequence analysis of the gadd45 promoter demonstrates a
GC-rich region that contains a consensus sequence for one WT1 and
three overlapping Egr-1 sites (35). It has been reported that this
GC-rich region is necessary for p53/WT1-dependent activation of the
gadd45 promoter (36). In addition, myc-mediated repression of
gadd45 also requires this GC-rich region (35). Our results demon-
strate that both the promoter and the putative p53-RE of the gadd45
gene are constitutively hypersensitive to DNase I, indicating that these
two regions have accessible chromatin structures. In addition, when
gadd45 was turned on, the promoter region appeared to be more
dynamic than the putative p53-RE. This suggested that chromatin
Fig. 6. p53-mediated activation of the gadd45 gene occurs from a nucleo-
some-free region. DNA in 2 3 10
6 isolated nuclei was digested with increasing
amounts of DNase I (0, 0.1, 0.5, 2, 8, or 16 mg as indicated above each lane). A,
nuclei were isolated from TR9-7 cells containing tetracycline (control) or after a
24-h withdrawal of tetracycline with overlapping 0.1 mM CPT treatment for the
l a s t4h( 2Tet & CPT). B, nuclei were isolated from 184A1 cells with (CPT)o r
without (Control) CPT for 4 h. Purified DNA was restricted with XbaI, electro-
phoresed on a 0.8% agarose gel, and probed with a
32P-labeled XbaI-MscI
genomic gadd45 probe fragment. C, schematic diagram of the genomic structure
of the human gadd45 gene showing the known and putative transcription factor
binding sites. The corresponding length detected by XbaI-MscI probing to the
gadd45 promoter region or putative p53-RE is also shown.
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have been involved in gadd45 gene activation from the promoter
when the DNA damage signal was present. The mdm2 P2 promoter is
constitutively sensitive to DNase I, but when p53 activates mdm2
transcription, no increase in this sensitivity occurs (17). Therefore,
increased DNase I sensitivity at the gadd45 promoter suggests that
p53 might function differently at various target genes. Chromatin
remodeling may act as one modulator to regulate gene expression of
p53-inducible genes.
DISCUSSION
p53 Requires a Damage Signal to Efficiently Activate gadd45.
DNA damage induces activation of p53 as a transcription factor and
also causes the activation of a number of p53-responsive genes. The
specific mechanism of how p53 is regulated to activate its many
downstream target genes remains unclear. The general paradigm is
that on activation, p53 levels increase concomitant with changes in
p53 posttranslational modification. DNA damage induces p53 to
activate gadd45 transcription, but it has been difficult to dissect the
type of p53 activation required because DNA damage generally
causes both an increase in the level of p53 and a number of p53
posttranslational modifications (37). Interestingly, we have found that
induced p53 in the absence of DNA damage does not significantly
activate the gadd45 gene. On the other hand, both the waf1/p21 and
mdm2 genes were activated in the absence of DNA damage. Tran-
scriptional activation of the gadd45 gene required both signals in-
duced by DNA damage and increased p53 levels. Using the p53-
inducible cell line TR9-7, we have demonstrated that the addition of
the topoisomerase I-targeted DNA-damaging agent CPT allowed for
the rapid activation of gadd45 without an increase in the intracellular
p53 level. It has previously been shown that an increase in p53 that
occurs without DNA damage is unable to activate gadd45 (38).
Therefore, this phenomenon is not restricted to one cell type. We also
demonstrated that CPT treatment of TR9-7 cells induced phosphoryl-
ation of p53 at serine 15 and acetylation at lysine 382. These changes
correlated with the accumulation of gadd45 mRNA. However, inhi-
bition of these posttranslational modifications by the addition of
wortmannin did not inhibit gadd45 activation. This is the first time
that efficient gadd45 mRNA induction has been shown to require a
signal initiated by drug-induced cellular DNA damage to augment wt
p53 activity.
Are the p53 Posttranslational Modifications Induced by DNA
Damage Necessary for gadd45 Activation? ATM kinase activity is
increased after DNA damage, and this causes phosphorylation of p53
at serine 15 in vitro (13, 14). Phosphorylation of serine 15 in AT
minus cells is delayed after IR (39). ATR and DNA-PK can phos-
phorylate p53 at both serine 15 and serine 37 in vitro (14, 15, 40).
Furthermore, it has been shown that phosphorylation of serine 15 in
vivo is induced by gIR, CPT, and UV IR (22, 39). DNA damage-
induced phosphorylation at the NH2 terminus is known to act in two
separate pathways. One pathway works at the level of reducing the
binding of MDM2 to the p53 protein (22), which inhibits the ability
of MDM2 to promote the degradation of p53 (8, 9). The second
pathway is involved in increasing the ability of p53 to recruit CBP/
p300, followed by increasing the overall level of acetylation of the
COOH terminus of p53 (20, 41). It has been suggested that DNA
damage can activate p53 as a transcription factor through signaling for
an NH2-terminal phosphorylation and COOH-terminal acetylation
cascade (20). gadd45 gene induction by IR is blocked by the protein
kinase inhibitor H7, suggesting that gadd45 gene activation is medi-
ated by a kinase (3). In our study, inhibition of phosphorylation at
serine 15 by wortmannin was observed not to inhibit the DNA
damage-induced accumulation of gadd45 mRNA. This observation
suggests that blocking the phosphorylation of p53 serine 15 by either
DNA-PK or ATM is not sufficient to inhibit p53-mediated gadd45
gene activation. Previous studies have demonstrated that single mu-
tations of individual NH2-terminal serines do not have significant
effects on the p53 transactivation capacity (42). The possibility cannot
be ruled out that wortmannin does not inhibit phosphorylation of the
critical amino acids of p53 required for activation of the gadd45 gene.
It will be interesting to investigate what effect inhibiting modification
at other phosphorylation sites has on the regulation of gadd45 gene
activation. The block of acetylation of p53 at lysine 382 also did not
have an inhibiting effect on gadd45 gene activation. This suggests that
the acetyltransferase activity of p300 associated with p53 may not be
necessary to initiate gadd45 induction.
No Increase in p53 DNA Binding Activity Occurs Coincident
with the Activation of gadd45. Posttranslational modification of p53
by acetylation is thought to disrupt the interaction between the
COOH-terminal domain and the central domain of p53 (27). This may
allow p53 to adopt an active conformation, which enhances the
sequence-specific DNA binding activity of the protein. p53 was
acetylated at lysine 382 after CPT treatment. Increased DNA binding
by p53 after CPT treatment was not observed. The increased DNA
binding data, documented previously, were obtained by comparing
latent bacterially or baculovirus produced p53 to in vitro acetylated
p53 (27, 20). The observation that p53 in the TR9-7 cells was not
reactive with PAb421 suggests that the protein was phosphorylated at
the COOH terminus (30). In vitro phosphorylation of the p53 COOH-
terminal region by protein kinase C can stimulate sequence-specific
DNA binding ability while inhibiting PAb421 reactivity (29). In this
way, the p53 protein in TR9-7 cells is conformationally different as
compared with latent p53. The COOH-terminal modification of the
p53 in the TR9-7 cell line may be involved in the inability of the p53
to activate gadd45 significantly in the absence of DNA damage.
However, PAb421 reactivity did not emerge after CPT treatment and
is therefore not required for the activation of the gadd45 gene.
Direct DNA binding of p53 to the gadd45 putative p53-RE was not
observed. This suggests that either direct p53 binding to the putative
binding element is not necessary for p53-mediated activation or that
the interaction of p53 with the gadd45 p53-RE is transient. This was
in agreement with a previous in vivo footprinting study (43) that was
unable to detect clear protection at the gadd45 p53-RE. The hyper-
cutting seen in the footprinting analysis that resulted when p53 was
induced strengthens the argument for a transient interaction of p53
with the gadd45 gene. The gadd45 putative p53 binding site was
confirmed by comparing homology to a published p53 consensus
sequence (38) as well as by testing in mobility shift assay, immuno-
precipitation, and transient transfection assays (4). It is possible that
p53 may bind to a different region of the gadd45 gene or that p53
binds to the putative binding site before the 4 h drug treatment time
point that we examined. Another possibility is that the gadd45 p53-RE
is only bound by p53 in a specific cell cycle stage. The TR9-7 cells
with induced p53 undergo growth arrest at both G1-S phase and G2-M
phase, resulting in a mixed population of cells (11). If the p53 DNA
binding assay were carried out at each cell cycle stage instead of in an
exponentially growing population, the answer of whether p53 is
bound to its putative binding site would be more definitive. p53 can
also participate in transcriptional induction of the gadd45 promoter in
the absence of direct DNA binding (36). Moreover, whereas some
genotoxic stress does not require p53 to activate gadd45, p53 has been
shown to always have a cooperative activation effect (44). Interest-
ingly, p53 cooperates with WT1 as well as BRCA1 to activate the
transcription of the gadd45 gene (36, 45). Here barely detectable
gadd45 induction by genotoxic stress was observed in the absence of
1717
p53 DOES NOT ACTIVATE gadd45 IN THE ABSENCE OF DNA DAMAGEp53, and barely detectable induction was observed in the presence of
p53 without genotoxic stress. Therefore, p53 must normally be coop-
erating with some other signal to initiate the rapid and robust activa-
tion of gadd45.
A Change in DNase I Sensitivity at the gadd45 Promoter Occurs
during DNA Damage Induction. Constitutive DNase I hypersensi-
tivity at the gadd45 promoter and the p53-RE was observed. This
suggests that this gene is “preprimed” for activation and that both
these regions require a relaxed chromatin structure for the gene to
function properly. The observation of increased accessibility for
DNase I at the gadd45 promoter region on DNA damage suggests that
chromatin changes occur at the promoter region, but the nature of
these changes is unclear. It is possible that changes occur because
repressing factors are released or because new factors are bound.
Activation of gadd45 expression occurs in a c-myc knockout cell
line (46). The promoter of the gadd45 gene can be activated by p53
in the absence of the putative p53-RE when WT1 is present (36). The
GC-rich region of the promoter required for WT1/p53-mediated ac-
tivation is also required for myc-mediated gadd45 repression (35, 47).
The gadd45 promoter lacks a TATA box (4, 47). The TATA-less
promoter organization differs from that of many other p53 target
genes, such as waf1, mdm2, and bax, which may influence how
gadd45 is regulated. It is possible that the activation of gadd45 by
stress is effected through the release of c-myc repression in addition
to p53 recruitment of basal transcription machinery in the absence of
a TATA box. This would be reminiscent of the inducible lactose
operon system in Escherichia coli that is both positively and nega-
tively regulated.
Differential Expression of p53-inducible Genes. mdm2 tran-
scription is reduced by the topoisomerase poison etoposide (10). We
have demonstrated that reduction of mdm2 expression occurs after
CPT treatment as well. Arriola et al. (10) proposed that mdm2 ex-
pression may be inhibited by bulky adduct damage to the template
because both the P1 and P2 promoters of mdm2 are DNase I hyper-
sensitive. However, this suggestion is not consistent with our obser-
vation that the gadd45 promoter (which is also constitutively DNase
I hypersensitive) is turned on in the presence of CPT. The model
proposed by Wu and Levine (48) is preferred, in which DNA damage
induces a repressor specific for mdm2, which will inhibit mdm2
transcription. It should be noted that to fully analyze p53 transcrip-
tional activity, the analysis of one target gene (or one means of p53
activation) is not enough. Coordinate repression and activation may
work to differentially regulate the complex pattern of expression of
p53 target genes. In an inducible BRCA1 system, gadd45 induction is
coincident with BRCA1 expression (45). This suggests that BRCA1
may be a more powerful activator of gadd45 than p53. Additionally,
DNA damage may activate endogenous BRCA1 so that it readily
cooperates with p53 to activate gadd45 transcription. Many hypoth-
eses for the mechanisms of p53-mediated gadd45 gene activation
remain to be tested. The phosphorylation-acetylation cascade involv-
ing p53 posttranslational modifications at serine 15 and lysine 382
does not appear to be critical for the regulation of p53-mediated
activation of gadd45, although it may be critical for other functions of
p53. gadd45 has recently been reported to bind and activate an
upstream regulator of c-Jun-NH2-terminal kinase/stress-activated pro-
tein kinase, thus triggering c-Jun-NH2-terminal kinase/stress-activated
protein kinase-dependent apoptosis (49, 45). When p53 is induced by
the withdrawal of tetracycline in TR9-7 cells, it directs the cells to
undergo G1-S-phase and G2-M-phase arrest (11). Therefore, it is not
surprising that no detectable activation of gadd45 was observed in
cells with induced p53. It is possible that in the presence of CPT, a
program directing the cells toward apoptosis is turned on. This might
necessitate the activation of gadd45.
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